Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 23 Carcinoma, Transitional Cell 15 Neoplasms 14 Ovarian Neoplasms 13 Carcinoma, Renal Cell 13 Urinary Bladder Neoplasms 12 Carcinoma, Merkel Cell 12 Squamous Cell Carcinoma of Head and Neck 11 Colorectal Neoplasms 8 Triple Negative Breast Neoplasms 7 Pancreatic Neoplasms 7 Neoplasm Metastasis 7 Melanoma 7 Stomach Neoplasms 6 Recurrence 5 Breast Neoplasms 5 Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Lymphoma, Non-Hodgkin 2 Kidney Neoplasms 2 Kidney Diseases 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Central Nervous System Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Ovarian Epithelial 2 Uveal Melanoma 1 Urothelial Cancer 1

Interventions

enfortumab vedotin 2 zimberelimab 1 sirtratumab vedotin 1 sacituzumab govitecan 1 pembrolizumab 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Metastatic Urothelial Cancer × avelumab × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡